Anavex Life Sciences Corp
AVXL7.900USD
0.0000.00%
收盘 10/31, 16:00（美东）报价延迟15分钟
674.75M总市值
亏损市盈率 TTM
关于 Anavex Life Sciences Corp 公司
Anavex Life Sciences Corp. 是一家临床阶段的生物制药公司，致力于通过将精准医疗应用于具有高度未满足需求的中枢神经系统 (CNS) 疾病来开发差异化疗法。该公司分析临床试验的基因组数据以识别生物标记物，并将其用于临床试验分析。其重点是开发阿尔茨海默病、帕金森病、精神分裂症、神经发育、神经退行性疾病和罕见疾病（包括雷特综合征）和其他中枢神经系统疾病的治疗方法。该公司有两个核心项目和两个种子项目。ANAVEX 2-73 正在开发为用于治疗雷特综合征等罕见疾病的口服液体每日一次配方，以及用于治疗阿尔茨海默病等疾病的口服每日一次胶囊配方。ANAVEX 3-71 是一种可穿透中枢神经系统的潜在疾病修饰疗法，用于治疗认知障碍。其其他候选药物包括 ANAVEX 1-41、ANAVEX 1066 和 ANAVEX 1037。
Anavex Life Sciences Corp简介
公司代码AVXL
公司名称Anavex Life Sciences Corp
上市日期Apr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
员工数量42
证券类型Ordinary Share
年结日Apr 13
公司地址630 5Th Avenue
城市NEW YORK
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编10111
电话18446893939
网址https://www.anavex.com
公司代码AVXL
上市日期Apr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
Anavex Life Sciences Corp公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
+2.89%
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.51M
+2.89%
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Investment Management (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
其他
78.96%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Investment Management (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
其他
78.96%
股东类型
持股股东
占比
Investment Advisor
23.94%
Investment Advisor/Hedge Fund
9.52%
Individual Investor
3.36%
Hedge Fund
3.04%
Research Firm
1.10%
Bank and Trust
0.83%
Pension Fund
0.21%
Insurance Company
0.04%
其他
57.97%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
365
33.21M
38.67%
-1.68M
2025Q2
355
34.98M
40.98%
-162.00K
2025Q1
362
35.10M
41.13%
+789.16K
2024Q4
351
32.45M
38.14%
-89.26K
2024Q3
337
29.80M
35.14%
-2.92M
2024Q2
337
29.64M
35.02%
-6.78M
2024Q1
332
34.88M
42.48%
+4.38M
2023Q4
335
28.85M
35.15%
-996.59K
2023Q3
331
28.07M
34.33%
-2.23M
2023Q2
335
28.30M
35.04%
-4.91M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
6.22M
7.24%
+237.96K
+3.98%
Jun 30, 2025
The Vanguard Group, Inc.
5.09M
5.92%
+204.62K
+4.19%
Jun 30, 2025
State Street Investment Management (US)
2.95M
3.43%
-265.45K
-8.26%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.02M
2.35%
+54.98K
+2.80%
Jun 30, 2025
Two Sigma Investments, LP
1.80M
2.09%
+428.37K
+31.31%
Jun 30, 2025
Missling (Christopher U)
1.51M
1.76%
+42.45K
+2.89%
Sep 11, 2025
Skarpelos (Athanasios)
1.31M
1.52%
--
--
Apr 25, 2025
Northwest Asset Management
1.02M
1.19%
+24.13K
+2.41%
Jun 30, 2025
Invesco Capital Management LLC
821.33K
0.96%
+306.26K
+59.46%
Jun 30, 2025
Northern Trust Investments, Inc.
715.06K
0.83%
+40.31K
+5.97%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
iShares Neuroscience and Healthcare ETF
1.32%
ALPS Medical Breakthroughs ETF
0.42%
SPDR S&P Biotech ETF
0.25%
iShares Micro-Cap ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Momentum Factor ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
iShares Russell 2000 Growth ETF
0.05%
查看更多
iShares Neuroscience and Healthcare ETF
占比1.32%
ALPS Medical Breakthroughs ETF
占比0.42%
SPDR S&P Biotech ETF
占比0.25%
iShares Micro-Cap ETF
占比0.16%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.14%
Vanguard US Momentum Factor ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.08%
Invesco Nasdaq Biotechnology ETF
占比0.08%
iShares Biotechnology ETF
占比0.07%
iShares Russell 2000 Growth ETF
占比0.05%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
